Cancer Stem Cell News Volume 3.45 | Nov 19 2014

Cancer Stem Cell News 3.45 November 19, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter

Researchers Identify Key Mechanism and Potential Target to Prevent Leukemia
Researchers have identified two proteins that appear crucial to the development – and patient relapse – of acute myeloid leukemia. They have also shown they can block the development of leukemia by targeting those proteins. [Press release from Indiana University discussing online prepublication in Cell Reports]
Press Release | Full Article | Graphical Abstract
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now

PUBLICATIONS (Ranked by impact factor of the journal)
miR-142 Regulates the Tumorigenicity of Human Breast Cancer Stem Cells through the Canonical WNT Signaling Pathway
Enforced expression of microRNA (miR)-142 or miR-150 in normal mouse mammary stem cells resulted in the regeneration of hyperproliferative mammary glands in vivo. Knockdown of endogenous miR-142 effectively suppressed organoid formation by breast cancer stem cells (BCSCs) and slowed tumor growth initiated by human BCSCs in vivo. [Elife] Full Article

Cancer Stem Cell-Like Phenotype and Survival Are Coordinately Regulated Byakt/FoxO/Bim Pathway
Researchers aimed to determine if elements of the PI3K-AKT pathway are necessary to maintain the cancer stem cell-like phenotype in breast tumor cells and for these cells to survive, bearing in mind that the identification of such elements is likely to be relevant to define future therapeutic targets. [Stem Cells] Abstract

Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma
Scientists clarified the role of downregulation of paired related homeobox 1 (PRRX1) expression in predicting prognosis and mediating cancer stem cell-like properties in hepatocellular carcinoma. [Ann Surg Oncol] Abstract

Hypoxia-Inducible Factors Modulate the Stemness and Malignancy of Colon Cancer Cells by Playing Opposite Roles in Canonical Wnt Signaling
Scientists examined the role played by hypoxia-inducible factors (HIFs) in malignant phenotype maintenance and canonical Wnt signaling. Under normoxia, they determined that both HIF-1α and HIF-2α are expressed in human colon cancer cells but not in their non-malignant counterparts. [PLoS One] Full Article

Genome-Wide Microarray Expression and Genomic Alterations by Array-CGH Analysis in Neuroblastoma Stem-Like Cells
Researchers enriched the cancer stem cell-like cell population content of two commercial neuroblastoma cell lines by the use of conditioned cell culture media for neurospheres, and compared genomic gains and losses and genome expression by array-CGH and microarray analysis, respectively [PLoS One] Full Article

Mesenchymal Stem Cells Promote Epithelial to Mesenchymal Transition and Metastasis in Gastric Cancer though Paracrine Cues and Close Physical Contact
Cancer cells acquired an “activated” carcinoma-associated fibroblasts phenotype after being in close contact with mesenchymal stem cells and enhancing tumor metastasis and growth in vivo. Paracrine signals also induced EMT and promoted transwell and trans-endothelial migration, the changes were dependent on β-catenin, MMP-16, snail and twist. [J Cell Biochem] Abstract

Selective ROS-Dependent p53-Associated Anticancer Effects of the Hypoxoside Derivative Rooperol on Human Teratocarcinomal Cancer Stem-Like Cells
Rooperol selectively inhibited the proliferation of NT2/D1 cells in a concentration-dependent manner and had no effect on either normal embryonic fibroblasts which are more restrictive pluripotent stem cells or on NCCIT p53-mutant embryonal carcinoma cells. [Invest New Drugs] Abstract

Identification of OLIG2 as the Most Specific Glioblastoma Stem Cell Marker Starting from Comparative Analysis of Data from Similar DNA Chip Microarray Platforms
Scientists carried out a comparative analysis based on the identification of inter-study concordances to identify the genes that exhibit at best differential levels of expression between glioma stem cell-enriched cell cultures and differentiated tumor cell cultures from independent studies using DNA chip microarray technologies. [Tumor Biol] Abstract

miR-21 Up-Regulation Mediates Glioblastoma Cancer Stem Cells Apoptosis and Proliferation by Targeting FASLG
The expression of microRNA (miR)-21 increased significantly in glioblastoma contrast to normal brain tissue, and miR-21 up-regulated in glioblastoma cancer stem cells (GSCs) remarkably. The proliferation of GSCs cell could be inhibited with high-expression of miR-21 and this effect could be restored by miR-21 knocked down. [Mol Biol Rep] Abstract

NeuroCult™ for Brain Tumor Research - View Publications

Tissue-Specific Stem Cells in the Myometrium and Tumor-Initiating Cells in Leiomyoma
The authors review current studies of myometrial and leiomyoma stem/progenitor cells and provide a new paradigm for understanding myometrial physiology and pathology and how these cells might contribute to uterine remodeling during pregnancy and the formation of leiomyomas. [Biol Reprod] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Nodality Develops Disease-Associated PD-1 Assay System for Application in Immuno-Oncology
Nodality, Inc. presented a newly-developed human cell-based system to quantitate PD-1 activity. Nodality’s Single Cell Network Profiling (SCNP) technology detected significant differences in PD-1+ T cell subset signaling when comparing samples from patients with chronic lymphocytic leukemia and healthy donors. [Press release from Nodality, Inc. discussing research presented at the 26th EORTC-NCI-AACR Symposium, Barcelona] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.

UAB Cancer Center and ASU Receive Grant to Address Cancer Health Disparities
The University of Alabama at Birmingham Comprehensive Cancer Center and Alabama State University have received a $1.5 million grant from the National Institutes of Health/National Cancer Institute that establishes a partnership to create a critical mass of research and researchers to reduce cancer health disparities in minorities. [The University of Alabama at Birmingham] Press Release

TapImmune Announces Phase II Clinical Trials Collaboration with VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
TapImmune, Inc. announced a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida) forming a partnership to advance TapImmune’s proprietary cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers. [TapImmune, Inc.]
Press Release

Juno’s JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA
Juno Therapeutics, Inc. announced that the FDA has granted orphan drug designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. [Juno Therapeutics, Inc.] Press Release

GlycoMimetics Announces Positive Top-Line Results from Phase I Study of GMI-1271 in Healthy Volunteers
GlycoMimetics, Inc. announced that healthy volunteers in a Phase I clinical study of GMI-1271 tolerated the drug candidate well, and that the pharmacokinetics for the drug candidate were as predicted based on preclinical data. [GlycoMimetics, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 2014 Pathology Congress
December 2-4, 2014
London, United Kingdom

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Energy Metabolism and Nutrient Sensing in Cancer Development and Stem Cells (MD Anderson Cancer Center)

Postdoctoral Fellow – Cancer Biology (Lund University)

Postdoctoral Position – Intestinal Stem Cell Biology and Gastrointestinal Malignancies (Albert Einstein College of Medicine of Yeshiva University)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Postdoctoral Position – Leukemic Stem Cells (BC Cancer Agency)

Assistant or Associate Professor – Cancer Biology (University of Pennsylvania)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us